Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers

World Journal of Biological Psychiatry

Volumn 5, Issue 3, 2004, Pages 149-154

  Maron, Eduard ^a   Tasa, Gunnar ^a   Tõru, Innar ^a   Lang, Aavo ^a   Vasar, Veiko ^a   Shlik, Jakov ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Cholecystokinin; Genetic polymorphism; Panic attacks; Serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; DNA; PLACEBO; SEROTONIN; SEROTONIN TRANSPORTER; TETRAGASTRIN; AMINE OXIDASE (FLAVIN CONTAINING); CARRIER PROTEIN; CHOLECYSTOKININ RECEPTOR; MEMBRANE PROTEIN; NERVE PROTEIN; PRIMER DNA; SLC6A4 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC REGULATION; GENOTYPE; HUMAN; MALE; PANIC; PATHOPHYSIOLOGY; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; GENETICS; METABOLISM; NERVE CELL NETWORK; SEX DIFFERENCE; UPREGULATION;

5-HYDROXYTRYPTOPHAN; ALLELES; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MONOAMINE OXIDASE; NERVE NET; NERVE TISSUE PROTEINS; PANIC DISORDER; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, CHOLECYSTOKININ; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX FACTORS; UP-REGULATION;

EID: 16544387116     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970410029927     Document Type: Article

References (35)

1. Bell, C and Nutt, D. (1998) Serotonin and panic Br J Psychiatry, 172, pp. 465-471.
2. Bradwejn, J and Koszycki, D and Shriqui, C. (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings Arch Gen Psychiatry, 48, pp. 603-610.
3. Bressa, G and Marini, S and Gregori, S. (1987) Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam Int J Clin Pharmacol Res, 7, pp. 111-119.
4. Catalano, M. (2001) Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism Eur Neuropsychopharmacol, 11, pp. 431-439.
5. Charney, D and Woods, S and Goodman, W and Heninger, G. (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects Psychopharmacology, 92, pp. 14-24.
6. Deakin, J and Graeff, F. (1991) 5-HT and mechanisms of defence J Psychopharmacol, 5, pp. 305-315.
7. Deckert, J and Catalano, M and Heils, A and Di Bella, D and Friess, F and Politi, E and Franke, P and Nöthen, M and Maier, W and Bellodi, L and Lesch, K. (1997) Functional promoter polymorphism of the human serotonin transporter: Lack of association with panic disorder Psychiatr Genet, 7, pp. 45-47.
8. Deckert, J and Catalano, M and Syagailo, Y and Bosi, M and Okladnova, O and Di Bella, D and Nöthen, M and Maffei, P and Franke, P and Fritze, J and Maier, W and Propping, P and Beckmann, H and Bellodi, L and Lesch, K. (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder Hum Mol Genet, 8, pp. 621-624.
9. den Boer, J and Westenberg, H. (1990) Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin Psychopharmacology, 102, pp. 85-94.
10. Fehr, C and Grintschuk, N and Szegedi, A and Anghelescu, I and Klawe, C and Singer, P and Hiemke, C and Dahmen, N. (2000a) The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy Psychiatry Res, 97, pp. 1-10.
11. Fehr, C and Szegedi, A and Anghelescu, I and Klawe, C and Hiemke, C and Dahmen, N. (2000b) Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study Psychiatr Genet, 10, pp. 59-65.
12. Germine, M and Goddard, A and Woods, S and Charney, D and Heninger, G. (1992) Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder Biol Psychiatry, 32, pp. 457-461.
13. Graeff, F and Guimaraes, F and De Andrade, T and Deakin, J. (1996) Role of 5-HT in stress, anxiety, and depression Pharmacol Biochem Behav, 54, pp. 129-141.
14. Hamilton, S and Heiman, G and Haghighi, F and Mick, S and Klein, D and Hodge, S and Weissman, M and Fyer, A and Knowles, J. (1999) Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder Psychiatr Genet, 9, pp. 1-6.
15. Hamilton, S and Slager, S and Heiman, G and Haghighi, F and Klein, D and Hodge, S and Weissman, M and Fyer, A and Knowles, J. (2000) No genetic linkage or association between a functional promoter polymorphism in the monoamine oxidase-A gene and panic disorder Mol Psychiatry, 5, pp. 465-466.
16. Hariri, A and Mattay, V and Tessitore, A and Kolachana, B and Fera, F and Goldman, D and Egan, M and Weinberger, D. (2002) Serotonin transporter genetic variation and the response of the human amygdala Science, 297, pp. 400-403.
17. Heinz, A and Jones, D and Mazzanti, C and Goldman, D and Ragan, P and Hommer, D and Linnoila, M and Weinberger, D. (2000) A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity Biol Psychiatry, 47, pp. 643-649.
18. Kahn, R and Wetzler, S and Asnis, G and Kling, M and Suckow, R and van Praag, H. (1991) Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects Psychiatry Res, 37, pp. 25-34.
19. Kent, J and Coplan, J and Gorman, J. (1998) Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety Biol Psychiatry, 44, pp. 812-824.
20. Klaassen, T and Klumperbeek, J and Deutz, N and van Praag, H and Griez, E. (1998) Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge Psychiatry Res, 77, pp. 167-174.
21. Koszycki, D and Zacharko, R and Le Melledo, J and Young, S and Bradwejn, J. (1996) Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers Biol Psychiatry, 40, pp. 648-655.
22. Lesch, K and Bengel, D and Heils, A and Sabol, S and Greenberg, B and Petri, S and Benjamin, J and Muller, C and Hamer, D and Murphy, D. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science, 274, pp. 1527-1531.
23. Maron, E and Kuikka, J and Shlik, J and Vasar, V and Vanninen, E and Tiihonen, J. (2003) Reduced brain serotonin transporter binding in patients with panic disorder Eur Neuropsychopharmacol, 13(Suppl 4), pp. 358-359.
24. Maron, E and Tõru, I and Vasar, V and Shlik, J. (2004) The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers J Psychopharmacology, 18, pp. 194-199.
25. Moreno, F and Rowe, D and Kaiser, B and Chase, D and Michaels, T and Gelernter, J and Delgado, P. (2002) Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion Mol Psychiatry, 7, pp. 213-216.
26. Neumeister, A and Bain, E and Nugent, A and Carson, R and Bonne, O and Luckenbaugh, D and Eckelman, W and Herscovitch, P and Charney, D and Drevets, W. (2004) Reduced serotonin type 1A receptor binding in panic disorder J Neurosci, 24, pp. 589-91.
27. Sabol, S and Hu, S and Hamer, D. (1998) A functional polymorphism in the monoamine oxidase A gene promoter Hum Genet, 103, pp. 273-279.
28. Sand, P and Lesch, K and Catalano, M and Bosi, M and Syagailo, Y and Okladnova, O and Di Bella, D and Maffei, P and Heils, A and Friess, F and Politi, E and Nöthen, M and Franke, P and Stöber, G and Fritze, J and Maier, W and Propping, P and Beckmann, H and Bellodi, L and Riederer, P and Deckert, J. (2000) Polymorphic MAO-A and 5-HT transporter genes: Analysis of interactions in panic disorder World J Biol Psychiatry, 1, pp. 147-150.
29. Schruers, K and Klaassen, T and Pols, H and Overbeek, T and Deutz, N and Griez, E. (2000) Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients Psychiatry Res, 93, pp. 179-187.
30. Schruers, K and van Diest, R and Overbeek, T and Griez, E. (2002) Acute 5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients Psychiatry Res, 113, pp. 237-243.
31. Sena, L and Bueno, C and Pobbe, R and Andrade, T and Zangrossi, H, Jr and Viana, M. (2003) The dorsal raphe nucleus exerts opposed control on generalized anxiety and panic-related defensive responses in rats Behav Brain Res, 142, pp. 125-133.
32. Shlik, J and Vasar, V and Aluoja, A and Kingisepp, P and Jagomagi, K and Vasar, E and Rago, L and Bradwejn, J. (1997) The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers Biol Psychiatry, 42, pp. 206-212.
33. Tadic, A and Rujescu, D and Szegedi, A and Giegling, I and Singer, P and Moller, H and Dahmen, N. (2003) Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression Am J Med Genet, 117B, pp. 1-6.
34. Targum, S and Marshall, L. (1989) Fenfluramine provocation of anxiety in patients with panic disorder Psychiatry Res, 28, pp. 295-306.
35. Tyrer, P and Shawcross, C. (1988) Monoamine oxidase inhibitors in anxiety disorders J Psychiatr Res, 22, pp. 87-98.